PE20220970A1 - Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones - Google Patents
Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulacionesInfo
- Publication number
- PE20220970A1 PE20220970A1 PE2022000318A PE2022000318A PE20220970A1 PE 20220970 A1 PE20220970 A1 PE 20220970A1 PE 2022000318 A PE2022000318 A PE 2022000318A PE 2022000318 A PE2022000318 A PE 2022000318A PE 20220970 A1 PE20220970 A1 PE 20220970A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- formulations
- compound
- pyrazol
- discloses
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 229940077388 benzenesulfonate Drugs 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001733 carboxylic acid esters Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000002467 interleukin receptors Human genes 0.000 abstract 1
- 108010093036 interleukin receptors Proteins 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- -1 pyrazole derivative compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894547P | 2019-08-30 | 2019-08-30 | |
| PCT/US2020/048528 WO2021041898A1 (en) | 2019-08-30 | 2020-08-28 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220970A1 true PE20220970A1 (es) | 2022-06-10 |
Family
ID=72473975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000318A PE20220970A1 (es) | 2019-08-30 | 2020-08-28 | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11370787B2 (https=) |
| EP (1) | EP4003990A1 (https=) |
| JP (2) | JP2022545542A (https=) |
| KR (1) | KR20220054626A (https=) |
| CN (2) | CN121159524A (https=) |
| AR (1) | AR119857A1 (https=) |
| AU (1) | AU2020335903A1 (https=) |
| BR (1) | BR112022003564A2 (https=) |
| CA (1) | CA3152264A1 (https=) |
| CO (1) | CO2022002993A2 (https=) |
| CR (1) | CR20220085A (https=) |
| DO (1) | DOP2022000047A (https=) |
| EC (1) | ECSP22014379A (https=) |
| IL (1) | IL290882B2 (https=) |
| JO (1) | JOP20220050A1 (https=) |
| MX (1) | MX2022002292A (https=) |
| PE (1) | PE20220970A1 (https=) |
| PH (1) | PH12022550466A1 (https=) |
| PY (1) | PY2049213A (https=) |
| SA (1) | SA522431791B1 (https=) |
| TW (1) | TWI870449B (https=) |
| WO (1) | WO2021041898A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20220970A1 (es) * | 2019-08-30 | 2022-06-10 | Rigel Pharmaceuticals Inc | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones |
| US12357623B2 (en) | 2021-03-03 | 2025-07-15 | Rigel Pharmaceuticals, Inc. | Method for treating a disease or condition using a pyrazole compound or formulation thereof |
| US20240382470A1 (en) * | 2021-09-08 | 2024-11-21 | Rigel Pharmaceuticals, Inc. | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus |
| IL315677A (en) | 2022-03-23 | 2024-11-01 | Rigel Pharmaceuticals Inc | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
| CN119950825B (zh) * | 2025-03-13 | 2025-07-22 | 北京工业大学 | 基于压电驱动的自适应释药电纺覆膜气管支架的制备方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| DK0431519T3 (da) | 1989-12-04 | 1994-07-04 | Searle & Co | System til transdermal indgivelse af albuterol |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| DE69228827T2 (de) | 1991-12-18 | 1999-10-21 | Minnesota Mining And Mfg. Co., Saint Paul | Mehrschichtige sperrstrukturen |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| WO2006070202A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
| EP2206707B1 (en) | 2007-10-24 | 2014-07-23 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| EP2070925A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
| WO2010121243A1 (en) | 2009-04-17 | 2010-10-21 | University Of Arizona | Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles |
| EP2243481A1 (en) | 2009-04-24 | 2010-10-27 | PamGene B.V. | Irak kinase family as novel drug target for Alzheimer |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| JP6161537B2 (ja) | 2010-04-07 | 2017-07-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法 |
| RU2632900C2 (ru) | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| EP2561102A1 (en) | 2010-12-02 | 2013-02-27 | Katholieke Universiteit Leuven K.U. Leuven R&D | Irak-related interventions and diagnosis |
| BR112013015460B1 (pt) | 2010-12-20 | 2022-01-25 | Merck Serono S.A. | Derivados de indazolil triazol, kit, e composição farmacêutica |
| WO2012097013A1 (en) | 2011-01-10 | 2012-07-19 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| BR112013020282A2 (pt) | 2011-02-09 | 2017-07-18 | Nissan Chemical Ind Ltd | derivado pirazol e agente de controle |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| JP6126131B2 (ja) | 2012-01-10 | 2017-05-10 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| AU2013322736A1 (en) | 2012-09-26 | 2015-02-26 | F. Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| EP2903613B1 (en) | 2012-10-08 | 2017-11-22 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of irak4 activity |
| HRP20171302T1 (hr) | 2013-02-07 | 2017-10-20 | Merck Patent Gmbh | Makrociklički derivati piridazinona |
| HUE032863T2 (en) | 2013-02-07 | 2017-11-28 | Merck Patent Gmbh | Piridazinonamid derivatives |
| EP3092225B1 (en) | 2014-01-09 | 2019-02-27 | Merck Patent GmbH | Pyrimidine pyrazolyl derivatives and their use as irak inhibitors |
| JP6787892B2 (ja) | 2014-11-20 | 2020-11-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用 |
| LT3286181T (lt) * | 2015-04-22 | 2021-04-26 | Rigel Pharmaceuticals, Inc. | Pirazolo junginiai ir junginių gamybos bei naudojimo būdas |
| JP7170634B2 (ja) * | 2016-10-26 | 2022-11-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｉｒａｋ阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法 |
| PE20220970A1 (es) | 2019-08-30 | 2022-06-10 | Rigel Pharmaceuticals Inc | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones |
-
2020
- 2020-08-28 PE PE2022000318A patent/PE20220970A1/es unknown
- 2020-08-28 MX MX2022002292A patent/MX2022002292A/es unknown
- 2020-08-28 KR KR1020227009706A patent/KR20220054626A/ko active Pending
- 2020-08-28 BR BR112022003564A patent/BR112022003564A2/pt unknown
- 2020-08-28 EP EP20771685.3A patent/EP4003990A1/en active Pending
- 2020-08-28 CN CN202511306178.3A patent/CN121159524A/zh active Pending
- 2020-08-28 IL IL290882A patent/IL290882B2/en unknown
- 2020-08-28 US US17/006,150 patent/US11370787B2/en active Active
- 2020-08-28 CR CR20220085A patent/CR20220085A/es unknown
- 2020-08-28 AR ARP200102424A patent/AR119857A1/es unknown
- 2020-08-28 WO PCT/US2020/048528 patent/WO2021041898A1/en not_active Ceased
- 2020-08-28 CA CA3152264A patent/CA3152264A1/en active Pending
- 2020-08-28 JP JP2022513277A patent/JP2022545542A/ja active Pending
- 2020-08-28 TW TW109129543A patent/TWI870449B/zh active
- 2020-08-28 AU AU2020335903A patent/AU2020335903A1/en active Pending
- 2020-08-28 CN CN202080061311.2A patent/CN114364674B/zh active Active
- 2020-08-28 PH PH1/2022/550466A patent/PH12022550466A1/en unknown
- 2020-08-28 PY PY202002049213A patent/PY2049213A/es unknown
-
2022
- 2022-02-23 EC ECSENADI202214379A patent/ECSP22014379A/es unknown
- 2022-02-25 DO DO2022000047A patent/DOP2022000047A/es unknown
- 2022-02-27 JO JOP/2022/0050A patent/JOP20220050A1/ar unknown
- 2022-02-28 SA SA522431791A patent/SA522431791B1/ar unknown
- 2022-03-15 CO CONC2022/0002993A patent/CO2022002993A2/es unknown
- 2022-05-18 US US17/747,384 patent/US20220306620A1/en not_active Abandoned
-
2023
- 2023-08-24 US US18/237,824 patent/US12441723B2/en active Active
-
2025
- 2025-11-25 JP JP2025203023A patent/JP2026053335A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2022000047A (es) | 2022-04-29 |
| US20210061798A1 (en) | 2021-03-04 |
| MX2022002292A (es) | 2022-06-02 |
| US20230399326A1 (en) | 2023-12-14 |
| CR20220085A (es) | 2022-04-19 |
| IL290882B1 (en) | 2025-11-01 |
| JP2022545542A (ja) | 2022-10-27 |
| BR112022003564A2 (pt) | 2022-05-17 |
| TWI870449B (zh) | 2025-01-21 |
| EP4003990A1 (en) | 2022-06-01 |
| IL290882A (en) | 2022-04-01 |
| PH12022550466A1 (en) | 2023-03-06 |
| AR119857A1 (es) | 2022-01-19 |
| WO2021041898A1 (en) | 2021-03-04 |
| AU2020335903A1 (en) | 2022-03-24 |
| ECSP22014379A (es) | 2022-05-31 |
| JOP20220050A1 (ar) | 2023-01-30 |
| JP2026053335A (ja) | 2026-03-25 |
| SA522431791B1 (ar) | 2025-04-14 |
| US20220306620A1 (en) | 2022-09-29 |
| KR20220054626A (ko) | 2022-05-03 |
| CN121159524A (zh) | 2025-12-19 |
| US12441723B2 (en) | 2025-10-14 |
| PY2049213A (es) | 2021-05-05 |
| CN114364674A (zh) | 2022-04-15 |
| IL290882B2 (en) | 2026-03-01 |
| CO2022002993A2 (es) | 2022-04-19 |
| CA3152264A1 (en) | 2021-03-04 |
| US11370787B2 (en) | 2022-06-28 |
| CN114364674B (zh) | 2025-10-03 |
| TW202122393A (zh) | 2021-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220970A1 (es) | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| ME00052B (me) | Derivati pirazolokarbokiseline kiseline, njihova priprema farmaceutske kompozicije sa sadržajem istih | |
| MX2021012756A (es) | Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este. | |
| KR20070116633A (ko) | 피지디2 길항제 활성을 갖는 1-아세틱 애시드-인돌 유도체 | |
| ATE540932T1 (de) | Hydantoin-derivate als antibakterielle wirkstoffe | |
| PE20200445A1 (es) | Inhibidores pirazolicos de magl | |
| CO2023004420A2 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| JP2016504400A (ja) | ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用 | |
| BR112022018515A2 (pt) | Terapia de combinação para leucemia mieloide aguda | |
| PE20251236A1 (es) | Formas cristalinas y sales de un agonista del receptor muscarinico | |
| PY2228191A (es) | Nuevos derivados de heteroaril aminopropanol | |
| BR112022001922A2 (pt) | Compostos de heteroarila de anel fundido como inibidores de ripk1 | |
| CO2023006912A2 (es) | Nuevos derivados de indazol acetileno | |
| CL2024001481A1 (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| PE20252682A1 (es) | Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlrp3 para el tratamiento de, por ejemplo, enfermedades inflamatorias | |
| HUE032472T2 (en) | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | |
| PE20251177A1 (es) | Inhibidores heterociclicos de sik | |
| JP5682555B2 (ja) | アルツハイマー病の治療剤又は予防剤 | |
| JP2017537104A (ja) | 変形性関節症におけるσ受容体リガンドの使用 | |
| MX2024013889A (es) | Derivado de anillo de benceno sustituido con imidazopiridazina, método de preparación, composición farmacéutica y uso | |
| BR112021014881A2 (pt) | Composto de poliol anti-hipertensivo e derivados do mesmo | |
| AR133698A1 (es) | COMPUESTOS Y COMPOSICIONES COMO AGENTES DEGRADANTES DE CBP / p300 Y USOS DE ESTOS | |
| SA522431667B1 (ar) | مركبات بيبريدينيل- ميثيل-بورين أمين في صورة مثبطات nsd2 وعوامل مضادة للسرطان | |
| JOP20250063A1 (ar) | مثبطات كيناز 7 المعتمدة على السيكلين |